Mouse Programmed cell death 1 ligand 1(CD274) ELISA kit

Code CSB-EL004911MO
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name CD274 molecule
Alternative Names Cd274 ELISA Kit; B7h1 ELISA Kit; Pdcd1l1 ELISA Kit; Pdcd1lg1 ELISA Kit; Pdl1Programmed cell death 1 ligand 1 ELISA Kit; PD-L1 ELISA Kit; PDCD1 ligand 1 ELISA Kit; Programmed death ligand 1 ELISA Kit; B7 homolog 1 ELISA Kit; B7-H1 ELISA Kit; CD antigen CD274 ELISA Kit
Abbreviation CD274
Uniprot No. Q9EP73
Species Mus musculus (Mouse)
Sample Types serum, plasma, tissue homogenates
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.81 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Others
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of mouse CD274 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 98  
Range % 92-105  
1:2 Average % 94  
Range % 88-97  
1:4 Average % 85  
Range % 80-89  
1:8 Average % 88  
Range % 83-95  
The recovery of mouse CD274 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 93 87-99  
EDTA plasma (n=4) 99 94-104  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected  
2000 2.805 2.650 2.728 2.560  
1000 2.404 2.375 2.390 2.222  
500 1.709 1.810 1.760 1.592  
250 0.994 1.008 1.001 0.833  
125 0.595 0.547 0.571 0.403  
62.5 0.372 0.355 0.364 0.196  
31.25 0.257 0.255 0.256 0.088  
0 0.171 0.164 0.168    
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
Gene References into Functions
  1. Immunogenic mouse neuroblastoma acquires adaptive immune resistance by up-regulating PD-L1 expression, whereas PD-L1 is of lesser consequence in nonimmunogenic neuroblastoma tumors. Combining PD-L1 checkpoint inhibition with whole tumor cell/anti-CTLA-4 vaccination enhanced tumor cell killing, cured mice with established tumors, and induced long-term immune memory (6 months). PMID: 29377881
  2. Data show that programmed cell death 1 ligand 1 (PD-L1) from disparate cellular sources, including tumour cells, myeloid or other immune cells can similarly modulate the degree of cytotoxic T-cell function and activity in the tumour microenvironment. PMID: 28220772
  3. IFNbeta activates neuronal PI3K/Akt signalling and Akt binds to transcription factor FoxA1 that translocates to the nucleus and induces PDL1. Conversely, inhibition of PI3K/Akt, FoxA1 and PDL1 blocked neuronal ability to generate FoxA1(+)Tregs. PMID: 28436428
  4. suppression of inflammatory responses and T cells apoptosis were observed with elevated expression of IRAK-M and PDL-1, and interference and neutralization of these 2 molecules led to partly reversed suppression of inflammation. PMID: 29995830
  5. The present work shows the role of SOCS1 in murine melanoma development and the potential of SOCS1-silenced tumor cells in raising an effective anti-melanoma immune response. PMID: 28079159
  6. miR-142 could attenuate cecal ligation and puncture-induced inflammation and thus sepsis via targeting PD-L1 in macrophages. PMID: 29793310
  7. T-cell activation mediates the immunopreventive effects of anti-PD-1; PD-1 on T cells interacts with the PD-1 ligand PD-L1 on cancer cells PMID: 29018057
  8. an enhanced expression of PD-L1 was observed besides an increased production of IFN-gamma by TH2 cells. PMID: 28917991
  9. Study demonstrated that PD-L1 expression is up-regulated in the salivary glands of female NOD mice during the developmental phase of Sjgren's syndrome, which in turn hinders the development and onset of this disease in a negative feedback fashion. PMID: 27966604
  10. PD-L1 expression on tumor cells suppressed antigen-driven TNF production by CD8(+) T cells, which could be antagonized through PD-1 blockade PMID: 28665401
  11. Anti-PD-1/PD-L1 therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 therapy, whereas implantation of CMT167 cells into PD-L1(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 in both the cancer cell and the microenvironment. PMID: 28819064
  12. In estrogen receptor negative breast cancer cells targeting of IL-17A inhibited PDL1 expression in the tumor microenvironment, decreasing the percentage of Treg cells in tumor-infiltrating lymphocytes, and promoting CD4+ and CD8+ T cells to secrete interferon gamma. PMID: 27935862
  13. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. PMID: 27835902
  14. Genetic ablation of a single immune-regulatory molecule in this model [i.e., B7-homolog 1 (B7-H1, PD-L1)] not only significantly increased incidence of spontaneous CNS autoimmunity and aggravated disease course, especially in the later stages of disease, but also importantly resulted in encephalitogenic T-cell infiltration and lesion formation in normally unaffected brain regions. PMID: 27671636
  15. Studied the possible role of PD-L1 on malignant melanoma initiating cells (MMICs). Found blocking of PD-L1 in melanoma cell lines impaired tumorsphere formation and induced the apoptosis. Also, blocking PD-L1 inhibited tumor growth in vivo. PMID: 29250533
  16. B7-H1 induction in keratinocytes may play a crucial role in the protection from CD4+ T cell-mediated tissue inflammation by exogenous antigens delivered from the mucosal surface in oral cavity PMID: 27731324
  17. Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells. PMID: 27295261
  18. Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR-155, Pdcd1, Pdcd1l1, and Ctla4 appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 = programmed cell death 1 protein; Pdcd1l1 = programmed cell death 1 ligand 1 protein; Ctla4 = cytotoxic T-lymphocyte-associated protein 4] PMID: 28912267
  19. spleen-derived IFN-gamma induces generation of PD-L1(+)-suppressive neutrophils. PMID: 28974543
  20. It was concluded that down-regulated expression of miR-143 and up-regulation of its direct target B7H1 may indicate a novel therapeutic method for radiation-induced thymic lymphoma by increased expression of miR-143 or inhibition of B7H1. PMID: 28736328
  21. HDAC6 inhibition reduces tumor growth and PD-L1 production in vivo. PMID: 26775640
  22. mediates an innate checkpoint to control adaptive T helper responses PMID: 28747424
  23. PD-L1 selectively enhances T cell-mediated immune responses, driving graft-versus-host disease lethality and suggesting a context-dependent function of the PD-1/PD-L1 axis PMID: 27294527
  24. Mesenteric lymph node CD11b(-) CD103(+) PD-L1(High) dendritic cell subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-beta activation. PMID: 28423181
  25. These results indicate that the outcome of PD-L1-mediated signaling in CD8+ T cells depends on the presence or absence of CD4+ T cells, the nature of the interacting receptor expressed by CD8+ T cells, and the tissue environment in which the signaling occurs. PMID: 28414296
  26. findings identify a previously unrecognized role of PD-L1 as an endogenous pain inhibitor and a neuromodulator. PMID: 28530662
  27. reduced cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is not just a marker of suppressed antitumor immunity. PMID: 28302645
  28. Apigenin inhibits IFN-gamma-induced PD-L1 expression by breast cancer cells, potentially rendering BC cells that lack constitutive PD-L1 expression more susceptible to T cellmediated anti-tumor immune responses. PMID: 27378243
  29. results reveal a novel CD40-dependent regulation of PD-L1 trafficking induced upon TLR3 signaling that dictates its inhibitory activity. PMID: 27911948
  30. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in a mouse model. PMID: 28254435
  31. PD-1/PD-L1 plays a crucial role in maintaining immune tolerance induced by UVB-iDCs, as well as in actively controlling effector T cells specific to alloantigens. PMID: 27556047
  32. Data show that Qiyusanlong decoction (QYSL) can moderately inhibit the growth of the transplanted tumor by decreasing programmed death 1 and programmed death ligand 1 (PD-1/PD-L1) level. PMID: 27371844
  33. Expression of PD-L1 is correlated with the severity of periodontitis in the mouse model of experimental periodontitis. PMID: 26847035
  34. Loss of Cdk5 results in persistent expression of the PD-L1 transcriptional repressors, the interferon regulatory factors IRF2 and IRF2BP2, which likely leads to reduced PD-L1 expression on tumors. PMID: 27463676
  35. addition to inhibiting T cells, hepatic stellate cells (HSCs) concurrently inhibit B cells via PD-L1; this direct B cell-inhibitory activity of HSCs should contribute to the mechanism by which HSCs maintain the liver's immune homeostasis PMID: 26755818
  36. The results demonstrated that blockade of PD-1/B7H1 pathway could promote mouse NK cells to kill the GL261GSCs, and the PD-1-inhibited NK cells could be a feasible immune therapeutic approach against Glioblastoma multiforme. PMID: 26266810
  37. These findings provide evidence for a novel immune escape mechanism during acute retroviral infection based on PD-L1 expression levels on virus infected target cells PMID: 26484769
  38. These results suggest a novel and specific role for PspA in modulating immune responses against S. pneumoniae by regulating PD-L1 expression. PMID: 26214513
  39. Upregulation of PD-1 and PD-L1 was associated with marked increases in GADD153 during myocardial ischemic reperfusion injury. PMID: 25902191
  40. Breg cells can suppress through the PD-1/PD-L1 pathway in limiting the differentiation and function of TFH cells PMID: 25609381
  41. Programmed death 1/programmed death ligand 1 pathway likely plays a crucial role in the mechanisms underlying spontaneous tolerization of B cells responding to ABO-blood group antigens in liver transplantation. PMID: 26247556
  42. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. PMID: 26378076
  43. the upregulation of IFN-beta in DCs induces the up-regulation of coinhibitory molecules B7H1 and GITRL, which cause an impaired activation of naive Ag-specific T cells PMID: 25144375
  44. IL-10 released from 18-month old mice stimulated the expression of B7-H1 on myeloid-derived suppressor cells PMID: 25479230
  45. PD-L1 expression is increased on tumor cells by direct contact with BM-derived CD11b-positive cells through the p38 signaling pathway. PMID: 25889536
  46. Our study defines PD-1 upregulated on Treg cells and its interaction with PD-1 ligand on effector T cells as one cause for the potent T cell suppression and proposes the role of PD-1 on Treg cells. PMID: 25934860
  47. Transduction of T cells with this new PD-1-CD28 receptor has the potential of breaking the PD-1-PD-L1-immunosuppressive axis in ACT. PMID: 26105028
  48. data reveal that PD-L1 is a critical modulator of Tregs' ability to suppress iALI, and this appears to involve SHP-1 activation. PMID: 25057927
  49. In experimental autoimmune uveitis, inducible Tregs use a PD-1/PD-L1 mechanism to suppress the disease. PMID: 25877928
  50. Immunological in vivo effects of B7-H1 deficiency PMID: 25173046

Show More

Hide All

Subcellular Location Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.
Protein Families Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity Highly expressed in the heart, thymus, skeletal muscle, and lung. Weakly expressed in the kidney, spleen, thyroid, and liver. Expressed on activated dendritic cells, B-cells and macrophages. Expressed in numerous tumor cells lines of lymphoid origin.
Database Links

KEGG: mmu:60533

STRING: 10090.ENSMUSP00000016640

UniGene: Mm.245363


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1